The working hypothesis of this study, therefore, is that the use of BRAF inhibitors in patients with metastatic melanoma presenting a BRAF mutation provokes the reinduction of acquired immunity against the tumour and that changes in immunological blood biomarkers indicate this re-establishment. Here, BRAF is linked to metastatic melanoma.